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Abstract: Constipation is a frequently overlooked side effect of clozapine treatment that can prove
fatal. We conducted a systematic review and meta-analysis to estimate the prevalence and risk factors
for clozapine-associated constipation. Two authors performed a systematic search of major electronic
databases from January 1990 to March 2016 for articles reporting the prevalence of constipation in
adults treated with clozapine. A random effects meta-analysis was conducted. A total of 32 studies
were meta-analyzed, establishing a pooled prevalence of clozapine-associated constipation of 31.2%
(95% CI: 25.6–37.4) (n = 2013). People taking clozapine were significantly more likely to be constipated
versus other antipsychotics (OR 3.02 (CI: 1.91–4.77), p < 0.001, n = 11 studies). Meta-regression
identified two significant study-level factors associated with constipation prevalence: significantly
higher (p = 0.02) rates of constipation were observed for those treated in inpatient versus outpatient
or mixed settings and for those studies in which constipation was a primary or secondary outcome
measure (36.9%) compared to studies in which constipation was not a specified outcome measure
(24.8%, p = 0.048). Clozapine-associated constipation is common and approximately three times more
likely than with other antipsychotics. Screening and preventative strategies should be established
and appropriate symptomatic treatment applied when required.
Keywords: constipation; clozapine; treatment-resistant schizophrenia; adverse events; systematic
review; meta-analysis
1. Introduction
Antipsychotic medication is the mainstay of the treatment of schizophrenia, but approximately 1/3
of people with schizophrenia fail to respond to non-clozapine antipsychotics and meet the criteria for
treatment-resistant schizophrenia (TRS) [1]. TRS is defined as non-response to at least two trials
of antipsychotic medication of adequate dose and duration [2]. Clozapine is the only effective
evidence-based treatment for TRS [3,4], and this is reflected in the clinical guidelines [2].
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Despite this, clozapine remains underused, with delays of up to four years reported between the
criteria for clozapine treatment being met and the first dose of clozapine [5]. One important reason
for this is the side effect burden associated with clozapine. Agranulocytosis is a rare, but potentially
fatal adverse effect of clozapine, with a cumulative incidence of 0.8% at 1 year and 0.38% over five
years [6,7]. Regular blood monitoring is required for the prescription of clozapine in many countries.
Other adverse effects include hypersalivation, metabolic disturbances including weight gain and
diabetes, sedation, seizures, and constipation [8].
Constipation is difficult, incomplete, or infrequent evacuation of dry, hardened feces and may
present with reduced frequency of defecation, slow stool transit time, abdominal bloating, and feelings
of incomplete evacuation [9]. It is an often disregarded, but common side effect of clozapine, with
a prevalence rate of 25% identified in a study of almost 500 clozapine-treated patients [10].
People with schizophrenia typically have several pre-existing risk factors for constipation,
including sedentary lifestyle, obesity, reduced fiber intake, and dehydration. Clozapine reduces
gastrointestinal motility, primarily via peripheral muscarinic anticholinergic activity [11], with M3
receptors in the gut wall being particularly affected [12–14]. This peripheral anticholinergic activity
inhibits the normal innervation of gut peristalsis, resulting in a hypomotile gut. Peripheral clozapine
serotonergic antagonism likely compounds the problem, as serotonin has a key role in gastrointestinal
motility [15] and reduces intestinal nociception [12]. Additionally, in vitro studies have suggested
that norclozapine, the major plasma metabolite of clozapine, may contribute to an increased risk for
constipation through potent agonist activity at δ opioid receptors [16]. The antimuscarinic activity of
clozapine may be more closely correlated with plasma clozapine and norclozapine concentrations than
with clozapine dose [17], although it is uncertain to what degree norclozapine exerts an antimuscarinic
effect [18]. Clozapine also acts as a strong histamine H 1 receptor antagonist, leading to sedation,
which is another possible contributing factor to constipation.
To compound the problem, symptoms of constipation and more severe gastrointestinal
hypomotility are often either not reported, or unrecognized. This may be due to patients’ unawareness
of physical problems due to cognitive deficits [19], core symptoms of schizophrenia [20], reduced
pain sensitivity associated with antipsychotic medication [12,21], a reduced ability to communicate
discomfort [22], or the failure of some clinicians to assess and treat physical health problems [19].
Standard side effect screening tools often omit questions on constipation [23], although recently
a screening specifically for clozapine, including a question on constipation [24], has been developed.
Constipation can lead to ileus, bowel obstruction, ischemic colitis, gastrointestinal necrosis, toxic
megacolon, and death [25–31]. The incidence of clozapine-related life-threatening hypomotility from
spontaneous reporting data in Australasia was 0.3% [12]. Nationwide hospital data in Denmark
reports the incidence of ileus with clozapine as 0.8% [32], a similar rate to that of clozapine-induced
agranulocytosis. In addition to its life-threatening consequences, constipation has a significant impact
on the quality of life [33,34].
A recent narrative review [35] suggested that constipation is a common side effect of antipsychotics
that is associated most frequently with clozapine treatment. However, this review was hallmarked by
the paucity of studies reporting on the proportion of clozapine-treated patients with constipation (one
review of five studies in China, two randomized control trials (RCTs), one observational study and two
case series). Further, when comparing prevalence rates of constipation between clozapine and other
antipsychotics, only one study reporting clozapine-associated constipation rates was included. Of the
other identified studies, only five provided prevalence rates (one of which was for severe constipation
only), and the other studies were case series or case reports. This was due to strict inclusion criteria,
namely that constipation was identified as a primary outcome in antipsychotic studies. This partly
reflects the reality of the lack of attention paid to this potentially fatal adverse event in clozapine
trials and observational studies as a primary or secondary outcome. However, to date a systematic
review has not been performed to assess either the prevalence of clozapine-associated constipation, or
factors that could help predict its occurrence. Furthermore, there are no meta-analytic data comparing
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risk of constipation with clozapine use to other antipsychotic treatments. The use of meta-analysis is
relevant as it enables the investigation of risk factors across a large number of studies and participants,
distinguishing risk factors associated with clozapine-associated constipation. Further, pooling data
allows for the investigation of the effect of demographic and study variables (gender, age, study
setting, geographical region, study design) and clinical variables (diagnoses, method of assessment
of clozapine associated constipation, duration of treatment, clozapine dosage and plasma clozapine
and norclozapine concentrations, smoking, and laxative use) on the risk of clozapine-associated
constipation, potentially allowing for risk stratification to be observed, which could aid clinicians in
monitoring for constipation in clozapine-treated patients. Given the aforementioned gaps within the
literature, we conducted a large-scale systematic review and meta-analysis.
The aim of this systematic review and meta-analysis was to assess the prevalence of constipation
associated with the use of clozapine and to compare this with the prevalence associated with
other antipsychotics. We anticipated completing separate subgroup analyses investigating the
pooled prevalence of clozapine-associated constipation in RCTs and studies that reported on the
prevalence rate of clozapine-associated constipation and conducted a comparative meta-analysis to
establish if constipation is more common in people treated with clozapine versus other antipsychotics.
We hypothesized that clozapine treatment would be associated with significantly greater risk of
constipation than treatment with other antipsychotics. In addition, we sought to identify potential
moderators of clozapine-associated constipation. We planned to perform subgroup analyses of the
prevalence of constipation according to geographical location, study design, study setting, and the
constipation assessment method used.
2. Methods
The review was conducted in accordance with the Meta-analysis of Observational Studies in
Epidemiology (MOOSE) guidelines [36] and reported in accordance with the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [37].
2.1. Inclusion and Exclusion Criteria
Included in the review were: (1) studies involving adults (age 18 years or more) with a diagnosis
of schizophrenia, schizoaffective disorder or a related psychotic disorder, or bipolar affective
disorder according to DSM or ICD classification, treated with clozapine; (2) comparative studies,
including RCTs, comparing clozapine treatment to a healthy control group or a group receiving
a non-clozapine antipsychotic; (3) non-comparative (without a control group) studies; (4) comparative
or non-comparative studies that reported a prevalence rate for clozapine associated constipation, not
necessarily as a primary or secondary study outcome; (5) studies that defined cases of constipation by
the following: patient self-report; checklist of adverse events; clinician or ICD diagnosis; consensus
criteria from Rome III criteria of at least 12 weeks of two or more of the following: (i) straining during
at least 25% of defecations; (ii) lumpy or hard stools in at least 25% of defecations; (iii) sensation of
incomplete evacuation for at least 25% of defecations; (iv) sensation of anorectal obstruction/blockage
for at least 25% of defecations; (v) manual maneuvers to facilitate at least 25% of defecations (e.g.,
digital evacuation, support of the pelvic floor); (vi) fewer than three defecations per week; laxative use
as a proxy measure for constipation; radiological evaluation by measures such as the colonic transit
test; and, (6) studies published in English in peer-reviewed journals since 1990.
Studies were excluded if (1) they did not provide sufficient data to ascertain the proportion
of clozapine-treated patients with constipation; or (2) data on constipation were presented with
anticholinergic data and not separately.
2.2. Information Sources and Searches
An electronic search using PubMed, Psychinfo, and Scopus was performed using different
combinations of the following search terms: Clozapine, Clozaril, constipat*, obstipation, laxatives,
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Intestinal obstruction, bowel obstruction, Ileus, paralytic ileus, anticholinergic (side) effect,
antimuscarinic (side) effect.
The electronic search was supplemented by a manual review of reference lists from eligible
publications including two Cochrane reviews and a recent narrative review [35,38,39].
2.3. Study Selection
Two independent authors screened the titles and abstracts of all potentially eligible articles.
Two authors applied the eligibility criteria, and a list of full text articles was developed through
consensus. The two reviewers then considered the full text of these articles, and a final list of included
articles was reached through consensus.
2.4. Data Extraction of Outcomes
The primary outcomes of interest were the point prevalence of clozapine associated-constipation,
as defined in the original reports, and the odds ratio (OR) of constipation in clozapine-treated patients
versus those treated with other antipsychotics.
Additionally, we extracted further data where possible to assess the study-level factors associated
with constipation prevalence in clozapine-treated patients. The data collected from each article
included: study design, geographical location, study setting, method of constipation assessment,
constipation data presented as a primary or secondary outcome or as side effects of clozapine treatment,
and details of clozapine participants (mean age, sex, mean dose and duration of clozapine use, mean
plasma clozapine and norclozapine concentrations of the study sample, percentage of smokers, and
the prevalence of those in receipt of laxatives).
To assess for differences between the prevalence of constipation based on the method of
constipation assessment, a binary variable was generated where studies were either categorized as
“more valid” or “less valid” in their approach to constipation assessment. Studies categorized as more
valid included studies in which the diagnostic definition of constipation was assigned through clinician
or ICD diagnosis, Rome III criteria, or by the proxy measure of laxative use. Studies categorized as
“less valid” included studies in which constipation was self-reported or assessed through the use of
checklists of adverse events.
When we identified a study that was eligible, but did not contain sufficient data to enable
inclusion in the meta-analysis, we contacted the corresponding authors twice over a month to acquire
the data [10,40–51].
2.5. Meta-Analysis
We pooled individual study data using the DerSimonian–Laird proportion method [52],
which calculates pooled prevalence of constipation using inverse-variance weighted random effects
meta-analysis with StatsDirect® and Comprehensive Meta-Analysis® software (version 3) (CMA
version 2, Englewood, NJ, USA). Due to the methodological variability in the included studies, we
anticipated heterogeneity, and a random effects meta-analysis was employed. We quantified any
observed heterogeneity by computing the I2 statistic [53].
We assessed publication bias using the Egger [54] tests, with a p-value <0.05 suggesting the
presence of bias. Finally, we conducted several meta-regression analyses (if N ě 4) to investigate
potential moderators of clozapine-associated constipation (age, sex, clozapine dose, plasma clozapine
and norclozapine concentrations, duration of clozapine use and the percentage of smokers, constipation
assessment method) with Comprehensive Meta-Analysis® (version 3). Despite a lack of consensus on
the number of studies required for meta-regression, we chose to only conduct meta-regression where
data was available from four or more studies based on recent recommendations [55].
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3. Results
3.1. Search Results and Study Selection
The initial search identified 1146 publications following removal of duplicates. Six hundred
and thirty titles and abstracts were screened, indicating 102 articles for full-text viewing. After the
application of the eligibility criteria, 32 of these studies were included in the systematic review.
Full details of the search process are summarized in Figure 1.
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3.2. Study and Participant Characteristics
Amongst the 32 studies included, 11 were trials that compared clozapine-treated patients to
patients treated with other antipsychotics, nine of which were RCTs. Twenty-one non-comparative
studies reported prevalence rates of clozapine-associated constipation. In total the dataset included
2013 patients treated with clozapine (comparative studies n = 935, non-comparative studies
n = 1078) and 964 patients treated with other antipsychotics. Details on the comparative and
non-comparative studies included and the participants in these studies reporting prevalence rates for
clozapine-associated con tipation are presented in Tables S1 and S2, respectively.
3.2.1. Included Studies—Non Comparative Studies
The sample size of the studies ranged from 15 [56] to 202 [57]. The mean age (data unavailable
from [58,59]) of participants was 39.2 years (range: 28.2 [60]–47.6 years [61]) and 71% were male
(gender data unavailable from [59]). The mean clozapine dose used (data missing from [59]) was
381 mg (SD = 138 mg). The mean plasma clozapine concentration was 0.46 (SD = 0.26) mg/L and the
mean plasma norclozapine concentration was 0.29 (SD = 0.17) mg/L.
This sample of non-comparative studies reporting prevalence rates of clozapine-associated
constipation included three RCTs [62–64]. This included one crossover study that compared two
different clozapine preparations (oral FazaClo versus Clozaril tablets) [62] and two studies that
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compared the use of clozapine alone to the use of clozapine augmented with another medication
(n = 1 augmented with risperidone, n = 1 augmented with minocycline). For our study, we extracted
data from the Clozaril-alone arm of the crossover study [62], as the prevalence of constipation
within both arms over the study was unclear and this arm provided more data. Additionally,
eight prospective studies [17,49,58,61,65–68], six retrospective cohort studies [48,50,56,57,59,69],
and four cross-sectional studies [24,70–72] were included. Of the 21 studies that reported on the
prevalence rate of clozapine-associated constipation, one was carried out across more than one
geographical region [63]. Five studies were carried out in Europe [24,57,63,68,70], seven in North
America [17,45,50,59,60,63–65,72], six in Asia [49,56,58,61,63,66], two in Africa [62,71], one in the
Middle East [48], and one in Oceania [69]. Nine studies were conducted in in-patient settings
(n = 395) [17,48–50,58–61,65], 10 involved outpatients (n = 627) [24,56,57,62,66,68–72], and two included
patients from mixed settings (n = 56) [63,64].
Five of the studies assessed for constipation or adverse effects of clozapine as a primary
outcome [24,57,59,70,71], while six other studies assessed for these as secondary outcome
measures [17,49,56,60,68,71]. Six studies used self-reports from patients to measure for
constipation [48,50,59,62,64,65], nine studies used a checklist to determine the presence or absence
of constipation in participants [17,24,56,60,63,66,69,70,72], and four screened for constipation using
structured clinical assessments [49,61,68,71]. One study identified constipation using laxative
prescription rates in patients [57], with only one other study reporting on laxative use [71].
3.2.2. Included Studies—Comparative Studies
The sample size of these studies ranged from 20 [73] to 956 [10]. The mean age of clozapine-treated
participants (37.5 years (age range 28.6 [74] to 46.1 years [51]) was similar to that of patients treated
with other antipsychotics (37.5 years (age range: 28.4 [74] to 41.7 years [51]). Sixty-nine percent of
those treated with clozapine and 65% of those treated with other antipsychotics were male. The mean
clozapine dose in clozapine-treated patients (from 10 studies (data missing from [74])) was 336 mg
(SD = 144 mg). Only one study reported plasma clozapine concentrations (0.49 (SD = 0.14) mg/L) [75]
and none of the comparative studies reported plasma norclozapine concentrations.
Of the 11 comparative studies, three were carried out across several geographical regions [10,76,77].
Five studies were conducted in North America [10,76,78–80], five in Europe [10,73,76,77,81], two in
South America [10,51], two in Africa [10,77], one in Oceania [75], and one in Asia [74]. Five
studies were conducted in in-patient settings (n = 263) [73–75,80,81], four involved out-patients
(n = 1186) [10,51,78,79], while two studies included participants from mixed settings (n = 450) [76,77].
Constipation was the primary outcome in two studies [51,75], and clozapine-related side effects
were the focus of one study [80]. Three studies measured clozapine-related side effects as
a secondary outcome [74,76,77]. Five studies determined constipation rates through self-reporting
by participants [10,73,76,77,81], while three studies used checklists [74,79,80], one used a structured
clinical assessment [78], and two [51,75] used the Rome III criteria to measure constipation rates.
From the Baptista study [51] we included the constipation rates determined using Rome III
diagnostic criteria of 33.3% in clozapine-treated patients and 12.5% in patients treated with other
antipsychotics (personal communication). This study also objectively assessed for gut hypomotility
using a colonic transit diagnostic test. Gut hypomotility was identified in 51% of clozapine-treated
patients compared to 31% in those treated with other antipsychotics, with no significant clozapine
dose relationship identified. In the Every–Palmer study [75], constipation was assessed for in several
ways. The data included in our meta-analysis were constipation rates identified using the Rome III
diagnostic criteria, with constipation identified in 57.9% of clozapine-treated patients compared to
23.5% of patients treated with other antipsychotics. However self-reporting in this study sample
identified constipation in only 20% of clozapine-treated patients compared to 17.6% of patients treated
with other antipsychotics, while laxative use was observed in 84.2% of clozapine-treated patients
compared to 17.6% of patients treated with other antipsychotics. Finally, the use of a colonic transit
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diagnostic test identified colonic hypomotility in 80% of clozapine-treated patients, compared to 0% of
patients treated using other antipsychotics.
4. Meta-Analysis
4.1. Prevalence of Constipation on Clozapine
Full details of the meta-analysis results are summarized in Table 1. It was possible to pool data
from 32 studies to establish that the point prevalence of clozapine-associated-constipation (n = 2013)
was 31.2% (95% CI: 25.6–37.4, I2 = 84%, 32 studies), with no evidence of publication bias (Egger = ´0.82,
p = 0.33).
Table 1. Subgroup analyses of moderators of constipation in people treated with clozapine.
Analysis Number of Study
Estimates
Meta-Analysis Heterogeneity Publication Bias
Prevalence 95% CI Between Groupp Value I
2 Egger Test
(p Value)
Main analysis 32 31.2 25.6 37.4 84 ´0.82 (p = 0.33)
Geographical
region 0.18
Europe 6 27.7 17.4 41.0 80 0.65 (p = 0.46)
North America 10 41.6 30.6 53.4 72 ´0.78 (p = 0.26)
South America 1 33.3 10.8 67.4 0 N/A
Asia 6 35.0 21.8 50.9 88 ´0.66 (p = 0.37)
Oceania 2 36.9 16.0 64.2 80 N/A
Africa 2 24.6 9.6 50.1 89 N/A
Middle East 1 11.9 2.9 37.7 0 N/A
Various 4 19.5 10.8 32.7 62 ´0.56 (p = 0.44)
Setting 0.02
Inpatient 14 40.5 31.4 50.4 87 ´0.66 (p = 0.46)
Outpatient 14 26.2 19.2 34.3 75 ´0.771 (p = 0.29)
Mixed 4 22.2 12.2 36.8 70 0.33 (p = 0.40)
Study design 0.31
Cross sectional 6 40.7 27.4 55.3 42 0.49 (p = 0.75)
Retrospective 6 28.2 17.2 42.6 81 ´0.51 (p = 0.67)
Prospective 8 34.4 23.3 47.6 85 ´0.44 (p = 0.23)
Randomized
control trial 12 25.9 18.3 35.4 80 ´0.88 (p = 0.46)
Constipation
method 0.70
Self-reported 11 26.7 18.2 37.2 59 1.13 (p = 0.15)
Checklist 12 34.7 24.7 46.4 90 ´0.59 (p = 0.33)
Clinician
diagnosis 6 28.4 16.5 44.1 81 0.419 (p = 0.09)
ROME III 2 43.1 11.1 70.1 62 N/A
Laxative use 1 35.2 11.1 70.3 0 N/A
N/A: Publication bias was only conducted where data was available from four or more studies.
Significantly higher rates of constipation were observed in inpatient settings (40.5%, 95% CI:
31.4–50.4, studies = 14, p = 0.02) than in outpatient (26.2%, 95% CI: 19.2–34.3, studies = 14) and mixed
settings (22.2%, 95% CI: 12.2–36.8, studies = 4). The mean clozapine dose used in the studies from
inpatient settings (n = 12) was 396 (SD = 134) mg/day, which was not significantly higher than the mean
dose used in outpatient settings (n = 14) (mean dose = 338 (SD = 113) mg/day (t = 1.201, p = 0.241).
There were no significant differences between mean serum clozapine (t = 1.455, p = 0.205) and mean
norclozapine concentrations (t = 2.487, p = 0.089) observed between inpatient and outpatient settings.
No significant difference in constipation was observed according to geographical region or study
design (full details in Table 1).
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Additionally, there were no significant differences observed in the prevalence of
clozapine-associated constipation between studies that used less valid methods to assess for
constipation (30.6%, 95% CI: 23.9–38.2, studies = 23, I2 = 85%, p = 0.79) compared to studies using more
valid assessment methods (32.5%, 95% CI: 22.0–45.1, I2 = 79%).
Contrastingly, significantly higher rates of constipation were observed in studies that described
constipation rates or side effects as a primary or secondary outcome measure (36.9%, 95% CI: 28.7–44.8,
studies = 18, I2 = 86%, p = 0.048) compared to studies that did not include them as specified outcome
variables (24.8%, 95% CI: 17.8–33.4, I2 = 65).
4.2. Prevalence of Constipation in Clozapine versus Other Antipsychotics
A comparative meta-analysis established that clozapine-treated patients (n = 935) were three
times more likely to have constipation (OR 3.02, 95% CI: 1.91–4.77, p < 0.001, 11 studies, I2 = 45%) than
those treated with other antipsychotics (n = 964) (Figure 2). The Egger bias test (0.24, p = 0.75) did not
indicate any publication bias.
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As shown in Figure 3, the risk for clozapine-associated constipation was greater for individuals
prescribed clozapine compared to those prescribed olanzapine (OR 3.13, 95% CI: 2.17–4.51, p < 0.001,
5 studies, I2 = 2%). The Egger bias test (0.24, p = 0.79) did not indicate any publication bias.
There were insufficient data to compare the risk between clozapine and other individual antipsychotics.
The individual studies demonstrated an increased risk for constipation in one study for clozapine (14%)
compared to risperidone (8.2%) [76], and in another study comparing clozapine (73.3%) to quetiapine
(12.5%) [74]. A slightly increased rate of constipation was identified for haloperidol-treated patients
(19%) compared to clozapine-treated patients (16.1%) in another study [79].
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4.3. Moderators of Clozapine-Associated Constipation across All Studies
Full details of the meta-regression analyses are presented in Table 2. Briefly, meta-regression
analyses did not identify any significant predictors of clozapine-related constipation.
Clozapine-associated constipation was not significantly related to the percentage of male patients
(β = 0.0081, 95% CI = ´0.0071–0.0233, p = 0.30, R2 = 0), mean age (β = 0.0090, 95% CI = ´0.0513–0.0693,
p = 0.77, R2 = 0.08), mean clozapine dose (β = 0.0017, 95% CI = ´0.0004–0.0039, p = 0.11, R2 = 0), mean
plasma clozapine concentration (β = 3.0455, 95% CI = ´0.6171–6.708, p = 0.10, R2 = 0.02), mean plasma
norclozapine concentration (β = 3.3561, 95% CI = ´1.6898–8.4021, p = 0.19, R2 = 0.01), duration of
clozapine treatment (β = 0.0013, 95% CI = ´0.0024–0.005, p = 0.49, R2 = 0), and percentage of smokers
(β = 0.0241, 95% CI = ´0.0039–0.0522, p = 0.0918, R2 = 0, n = 8 studies).
Table 2. Meta-regression of moderators of constipation.
Moderator Number of Studies β 95% CI p Value R2
Mean age 30 0.0090 ´0.0513 0.0693 0.7704 0.08
Percentage of males 31 0.0081 ´0.0071 0.0233 0.2953 0
Percentage of smokers 8 0.0241 ´0.0039 0.0522 0.0918 0
Clozapine mean dose 30 0.0017 ´0.0004 0.0039 0.1085 0
Plasma clozapine 9 3.0455 ´0.6171 6.708 0.1032 0.02
Plasma norclozapine 7 3.3561 ´1.6898 8.4021 0.1924 0.01
Number of weeks clozapine treatment 28 0.0013 ´0.0024 0.005 0.4888 0
% Sample schizophrenia 27 ´0.0020 ´0.0161 0.0121 0.7825 0
% Sample schizoaffective disorder 11 ´0.0009 ´0.0223 0.0204 0.9332 0
5. Discussion
5.1. General Findings
This is the first systematic review and meta-analysis to investigate clozapine-associated
constipation, and provides the most comprehensive assessment of the prevalence of and risk factors
for this condition. Our study identified that 31.2% of clozapine-treated patients had constipation when
surveyed. Our findings also established that constipation is three times more likely in those treated
with clozapine compared to treatment with other antipsychotics (OR 3.02, p < 0.001). Further, we
identified a threefold increased likelihood of constipation in those treated with clozapine compared to
olanzapine (OR 3.13, p < 0.001).
From the subgroups analyses, significantly higher rates of constipation were observed in those
treated in inpatient compared to outpatient or mixed settings. The variation in constipation rates by
study setting could not be explained by variations in mean clozapine doses or plasma clozapine and
norclozapine concentrations. A possible contributory factor may have been increased vigilance among
clinical staff in inpatient settings, with the use of monitoring tools such as the Bristol Stool Chart and
questioning about constipation as part of routine clinical practice, which may have led to an increased
subjective awareness of constipation in patients. Variation in lifestyle factors such as diet and exercise
habits may have further contributed to this difference in the reported incidence of constipation, but it
was not possible to study this further from the data available. We found no significant differences in
constipation rates according to study design or geographical region.
In meta-regression analyses, age, sex, diagnosis, percentage of smokers, duration of treatment,
clozapine dose, and plasma clozapine and norclozapine concentrations did not predict constipation.
Some of these results, in particular clozapine dose and plasma clozapine/norclozapine concentrations,
are surprising.
Our systematic review identified 11 eligible controlled studies published between 1998 and 2016.
However, we also identified that scant attention is paid to this adverse event in clozapine RCTs
as constipation rates are often either not reported, or not reported separately from anticholinergic
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group effects. This mirrors the previously identified underreporting of anticholinergic side effects in
antipsychotic randomized trials [82]. Given the high prevalence of clozapine-associated constipation
identified in this meta-analysis, the failure of clozapine RCTs to systematically assess for this adverse
event needs to be addressed, as does the variable rates of screening for constipation in clinical practice.
Notably, very few studies have assessed clozapine-associated constipation as a primary outcome, or,
with the exception of case reports, investigated its prognostic implications. Future research would
benefit greatly if standardization for the reporting of constipation could be reached, both in its inclusion
as an adverse event outcome and its method of measurement.
5.2. What this Study Adds
A previous narrative review of antipsychotic use and constipation concluded that constipation
is most frequently associated with clozapine [35]. Our meta-analysis builds on this conclusion in
a number of ways.
Firstly, we were able to pool data from 11 studies and establish that the prevalence of
constipation is significantly increased in clozapine-treated patients compared to those treated with
other antipsychotics; Secondly, we have established that the pooled prevalence is 31.2%, higher
than the 14.7%–17.1% identified in studies of the general population [83,84], particularly since these
studies showed higher prevalence rates in older people, compared to the younger mean age of people
identified in our study; Thirdly, we were able to conduct meta-regression analyses to investigate
potential moderators for these relationships. However, due to the paucity and inconsistency of
the reporting of possible risk factors, in particular plasma clozapine concentrations, our moderator
analyses did not enable us to identify any study-level predictors for clozapine associated constipation,
other than study setting. However, it is important to emphasize that the lack of associations between
studies does not constitute evidence of a lack of association at the patient level within each study.
For example, while we did not find an association between constipation risk and mean clozapine
dose or plasma clozapine concentration at the study level, this does not preclude the existence of
associations at the patient level within each study.
5.3. Clinical Implications
This study has highlighted the high rates of constipation that occur with clozapine compared
to other antipsychotic medication. Constipation, if untreated, can lead to life-threatening
complications [13]. The use of clozapine in schizophrenia is associated with a doubled risk for
ileus (OR 1.99, 95% CI: 1.21–3.29) and a 7-fold increased risk for fatal ileus (OR 6.73, 95% CI:
1.55–29.17) compared with other psychotropic medication [32,85], adverse events that are preceded
by constipation.
A systematic review (Cohen et al., 2012) indicated that while the incidence of agranulocytosis is
0.95–2 times more likely than gastrointestinal hypomotility, the case-fatality rate of gastrointestinal
hypomotility of 15.0%–35.7% is estimated to be approximately 10 times higher than that of
agranulocytosis (case fatality rate of 2.2%–4.2%). A reason for the reduced case fatality
with clozapine-induced agranulocytosis compared to that associated with clozapine-induced
gastrointestinal hypomotility is likely related to the early recognition of the condition from the regular
hematological monitoring required in many countries, a systemic screening approach that has yet to
be incorporated for the monitoring of constipation.
Despite this increased case fatality rate secondary to gastrointestinal hypomotility, and the high
rate of constipation identified in our meta-analysis, clozapine treatment guidelines rarely mention
constipation, and few recommend screening patients for constipation [35] or give advice on the
active management of it when it occurs. To our knowledge, the only current guidelines to recommend
screening are Dutch guidelines for the monitoring of physical health with antipsychotic use [86] and the
Maudsley Prescribing Guidelines [87], although recently a screening specifically for clozapine-related
adverse effects, including a question on constipation, has been developed [24].
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Case reports have highlighted the sudden onset of life-threatening symptoms due to undetected
constipation in clozapine-treated patients, with few reporting constipation to their clinicians
before-hand [25]. This could be due to either insufficient monitoring or to an impaired ability
to communicate symptoms [22], reduced pain sensitivity possibly being a factor here [21].
Each component should be considered when assessing constipation in clozapine-treated patients.
Not only is the outcome from untreated constipation potentially fatal, but as a medication side
effect it can contribute to treatment non-adherence, which can have a particularly devastating impact on
clinical stability in clozapine-treated patients [88]. Constipation in the general population is considered
an important health problem, with well-established diagnostic criteria [89], and it has been shown to
affect both socioeconomic and clinical outcome as well as subjective health-related quality of life [34].
However, there has not been a similar level of acknowledgment for clozapine-related constipation.
Our findings reinforce the need for active screening for constipation in clozapine-treated patients.
Firstly patients, staff and community carers or family members must be educated on the risk of
constipation and informed of the possible complications of untreated constipation. When prescribing
clozapine, the concurrent use of medications known to increase the risk of constipation should
be minimized. Specific attention should be paid to the use of anticholinergic treatments used for
clozapine-related hypersalivation. Further, caution should be taken in those with a history of
gastrointestinal disease or lower abdominal surgery. Changes in smoking habit should be noted,
and the clozapine dose adjusted accordingly [90]. Clozapine is largely metabolized by cytochrome
P (CYP) 1A2 enzymes. Polycyclic aromatic hydrocarbons in cigarette smoke are a potent inducer of
CYP1A2, and this high inducibility of CYP1A2 in smokers leads to increased clozapine metabolism
and decreased plasma concentrations [90,91]. The effect of starting or stopping smoking is important,
in that non-smokers who start smoking risk losing the benefit of clozapine in two to three days;
conversely, those who stop smoking are at risk of clozapine toxicity, which may include seizures,
unless the dose is adjusted promptly. Further, those who stop smoking are already at an increased
risk of constipation due to a reduction in bowel motility [92], and this allied to the increased plasma
clozapine concentrations that occur without dose reduction may put individuals at increased risk of
clozapine-associated constipation.
Protocols for monitoring constipation in clozapine-treated patients should be implemented when
clozapine initiation takes place. This may utilize the Bristol stool chart, a widely used system to
monitor stool frequency and consistency [93]. Clinicians as part of routine clinical practice should
actively ask about symptoms of constipation, including the frequency and difficulty of defecation.
Two of the studies included in this review objectively measured gastrointestinal hypomotility
using colonic transit tests. The diminished intestinal propulsive activity seen with hypomotility appears
to be an underlying mechanism for clozapine-associated constipation and its associated morbidity
and mortality. Both these studies found high rates of gastrointestinal hypomotility (50%–80%). Of the
51% individuals objectively hypomotile in one of these studies, 43.5% were negative for constipation
diagnosed using the Rome III criteria [51]. In the other study [75], while 80% of the sample showed
gastrointestinal hypomotility, only 58% of the same sample were positive for constipation using the
Rome III criteria, and only 20% of individuals self-reported constipation. Findings from both studies
indicate that constipation symptoms may not be sufficiently sensitive predictors of objective pathology.
Clozapine-treated patients should be regularly advised to increase their fluid and fiber intake, and
physical activity as an aid to prevent constipation. More liberal use of laxatives, even in combination,
for constipation may be necessary to prevent the progression of constipation. In the case of mild
constipation, a bulking agent may be sufficient. However, where symptoms persist, a stool softener
or laxative may be used [12]. Where constipation is more severe, stimulant cathartics, such as senna,
or enemas may be required. Some other treatments found to be effective include lubiprostone [85],
orlistat [94], and bethanechol [95]. However, despite the common use of laxatives and other treatments
for constipation in the general population, robust, well-replicated evidence for their effectiveness is
lacking [96]. These deficits in the literature are more pronounced in interventions for clozapine and
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other antipsychotic-related constipation, where no systematic review of treatment interventions has
been performed to date [97]. However, we advocate that the liberal use of laxatives is appropriate,
either singly or in combination.
If patients present with severe abdominal pain, they should be referred for a medical or surgical
assessment to exclude intestinal pathology, which can rapidly lead to death. Surgical intervention
may be required. Ultimately, clinicians must be made more aware of the hazards associated with
constipation to minimize its potential consequences; early screening and monitoring should decrease
constipation rates to improve the comfort, satisfaction, and adherence of patients, and avoid the
progression to a stage requiring surgery.
5.4. Future Directions
There is a need for evidence-based research on the management of constipation in clozapine
treated patients. Future research must address possible preventative measures, both lifestyle
and pharmacotherapeutic interventions. Additionally, our study has indicated the need for
clinical guidelines to be updated to reflect the need for systematic monitoring and treatment of
clozapine-associated constipation.
5.5. Limitations
Firstly, there were a wide variety of assessment methods used to record constipation, which
included patient self-reported, side effects checklists, clinician diagnosis, Rome III criteria, or using
laxative prescription rates to ascertain rates of constipation. Only two studies [51,75] measured
constipation using the Rome III criteria. The lack of use of methods of assessment such as the
Rome III criteria, which is a preferred method to assess for constipation, is a limitation of our
review and meta-analysis, although we did not identify a significant difference in the prevalence
rates of constipation identified in studies using more and less valid assessment methods to
diagnose constipation.
Secondly, there were a limited number of studies reporting important moderators such as plasma
clozapine and norclozapine concentration. In particular, this limitation may suggest that our finding of
a lack of association between increased plasma clozapine concentrations and constipation may have
been a type II error. Further, it is important to consider a limitation of meta-regression analyses across
studies, in that that the relationship between constipation and the average patient plasma clozapine
concentrations from across studies may not be the same as the relationship with individual patient
plasma concentrations from within studies, particularly when averages of patient characteristics in
each study were used as covariates in the regression [98].
Thirdly, only six studies focused on constipation as a primary outcome or secondary outcome.
Four studies focused on clozapine side effects (including constipation) as a primary outcome, while
eight studies included side effects (including constipation) as a secondary outcome. Fourteen studies
did not measure either constipation or side effects as specified outcome measures. Meta-analysis
showed significantly higher rates of constipation in studies that listed either constipation or
side effects as an outcome variable (36.9%, p = 0.048) compared to studies that did not (24.8%).
The higher rates identified in those studies may reflect a truer estimate of the prevalence of
clozapine-associated constipation, and the prevalence of constipation identified in this meta-analysis
may be an underestimate. However, our work in providing a more comprehensive review of the
literature has identified higher prevalence rates than the rate of 21.3% identified by De Hert et al. [35],
and likely offers the most valid estimation of the rate of clozapine-associated constipation in
the literature.
Further, there was limited information on other potentially important moderators of constipation
such as physical activity and diet. Additionally, high heterogeneity was found across the studies
included in the meta-analysis and disparate sample sizes were identified, though heterogeneity was
evenly distributed across studies with different assessment methods.
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6. Conclusions
Our systematic review and meta-analysis have demonstrated an increased risk of constipation in
people treated with clozapine. Clozapine-associated constipation is a more frequent adverse effect
than is recognized by many clinicians. Awareness of this important side effect needs to increase,
because early detection and management are key to minimizing risk. We did not identify a relationship
between plasma clozapine concentrations and constipation, though this was likely due to a paucity of
studies reporting this variable. There is a need for future prospective research to better understand
this relationship and the implications of smoking cessation without a corresponding decrease in
clozapine dose. Future research focusing on interventions for clozapine-associated constipation is
needed. Screening and preventative strategies should be established and appropriate symptomatic
treatment applied when required.
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